KR20180133413A - PDE1 억제제로서의 1,5-디히드로-4H-피라졸로[3,4-d]피리미딘-4-온 및 1,5-디히드로-4H-피라졸로[4,3-c]피리딘-4-온 - Google Patents

PDE1 억제제로서의 1,5-디히드로-4H-피라졸로[3,4-d]피리미딘-4-온 및 1,5-디히드로-4H-피라졸로[4,3-c]피리딘-4-온 Download PDF

Info

Publication number
KR20180133413A
KR20180133413A KR1020187029341A KR20187029341A KR20180133413A KR 20180133413 A KR20180133413 A KR 20180133413A KR 1020187029341 A KR1020187029341 A KR 1020187029341A KR 20187029341 A KR20187029341 A KR 20187029341A KR 20180133413 A KR20180133413 A KR 20180133413A
Authority
KR
South Korea
Prior art keywords
methyl
pyrazolo
pyridin
tetrahydropyran
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020187029341A
Other languages
English (en)
Korean (ko)
Inventor
카르스텐 율
미켈 예싱
모르텐 랑고르
파울로 호르헤 비에이라 비탈
마우로 마리고
얀 케흘러
라르스 퀸 라스무센
Original Assignee
하. 룬드벡 아크티에셀스카브
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 하. 룬드벡 아크티에셀스카브 filed Critical 하. 룬드벡 아크티에셀스카브
Publication of KR20180133413A publication Critical patent/KR20180133413A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020187029341A 2016-04-12 2017-04-07 PDE1 억제제로서의 1,5-디히드로-4H-피라졸로[3,4-d]피리미딘-4-온 및 1,5-디히드로-4H-피라졸로[4,3-c]피리딘-4-온 Ceased KR20180133413A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201600221 2016-04-12
DKPA201600221 2016-04-12
PCT/EP2017/058332 WO2017178350A1 (en) 2016-04-12 2017-04-07 1,5-dihydro-4h-pyrazolo[3,4-d]pyrimidin-4-ones and 1,5-dihydro-4h-pyrazolo[4,3-c]pyridin-4-ones as pde1 inhibitors

Publications (1)

Publication Number Publication Date
KR20180133413A true KR20180133413A (ko) 2018-12-14

Family

ID=58489694

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187029341A Ceased KR20180133413A (ko) 2016-04-12 2017-04-07 PDE1 억제제로서의 1,5-디히드로-4H-피라졸로[3,4-d]피리미딘-4-온 및 1,5-디히드로-4H-피라졸로[4,3-c]피리딘-4-온

Country Status (43)

Country Link
US (3) US20170291901A1 (enExample)
EP (1) EP3442975B1 (enExample)
JP (1) JP7093306B2 (enExample)
KR (1) KR20180133413A (enExample)
CN (1) CN109071549B (enExample)
AR (1) AR108109A1 (enExample)
AU (1) AU2017250431B2 (enExample)
BR (1) BR112017026278A2 (enExample)
CA (1) CA3020053A1 (enExample)
CL (1) CL2018002881A1 (enExample)
CO (1) CO2018010323A2 (enExample)
CR (1) CR20180470A (enExample)
CY (1) CY1123269T1 (enExample)
DK (1) DK3442975T3 (enExample)
DO (1) DOP2018000201A (enExample)
EA (1) EA035197B1 (enExample)
EC (1) ECSP18074641A (enExample)
ES (1) ES2814289T3 (enExample)
GE (2) GEAP201914901A (enExample)
HR (1) HRP20201331T1 (enExample)
HU (1) HUE050320T2 (enExample)
IL (1) IL262257B (enExample)
LT (1) LT3442975T (enExample)
MA (1) MA44656B1 (enExample)
ME (1) ME03820B (enExample)
MX (1) MX374251B (enExample)
MY (1) MY194722A (enExample)
NI (1) NI201800092A (enExample)
PE (1) PE20181853A1 (enExample)
PH (1) PH12018502168A1 (enExample)
PL (1) PL3442975T3 (enExample)
PT (1) PT3442975T (enExample)
RS (1) RS60714B1 (enExample)
RU (1) RU2018133391A (enExample)
SG (1) SG11201808221QA (enExample)
SI (1) SI3442975T1 (enExample)
SM (1) SMT202000446T1 (enExample)
SV (1) SV2018005753A (enExample)
TN (1) TN2018000321A1 (enExample)
TW (1) TWI729109B (enExample)
UA (1) UA121925C2 (enExample)
WO (1) WO2017178350A1 (enExample)
ZA (1) ZA201806407B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201629064A (zh) 2014-10-10 2016-08-16 Ｈ 朗德貝克公司 作爲ｐｄｅ１抑制劑之三唑並吡酮
JO3627B1 (ar) 2015-04-30 2020-08-27 H Lundbeck As إيميدازو بيرازينونات على هيئة مثبطات pde1
TWI729109B (zh) 2016-04-12 2021-06-01 丹麥商Ｈ 朗德貝克公司 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮
US10633382B2 (en) 2016-10-18 2020-04-28 H. Lundbeck A/S Imidazopyrazinones, pyrazolopyrimidinones and pyrazolopyridinones as PDE1 inhibitors
RU2019108717A (ru) 2016-10-28 2020-11-30 Х. Лундбекк А/С Комбинированные средства для лечения, предусматривающего введение имидазопиразинонов
LT3532064T (lt) 2016-10-28 2020-09-25 H. Lundbeck A/S Kompleksiniai gydymai, apimantys imidazopirazonus, skirti psichiatrinių ir (arba) kognityvinių sutrikimų gydymui
EP3562828B1 (en) 2016-12-28 2026-03-18 Dart Neuroscience LLC Substituted pyrazolopyrimidinone compounds as pde2 inhibitors
MX2020005447A (es) 2017-11-27 2020-12-03 Dart Neuroscience Llc Compuestos de furanopirimidina sustituida como inhibidores de pde1.
JP7493460B2 (ja) 2018-05-25 2024-05-31 イントラ－セルラー・セラピーズ・インコーポレイテッド 有機化合物
US20220184240A1 (en) 2019-04-12 2022-06-16 Intra-Cellular Therapies, Inc. Organic compounds
CN115304607B (zh) * 2022-07-06 2023-06-27 华南农业大学 吡唑并嘧啶衍生物的制备方法

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB973361A (en) * 1960-05-11 1964-10-28 Ciba Ltd Pyrazolo-pyrimidines and process for their manufacture
DE19709877A1 (de) 1997-03-11 1998-09-17 Bayer Ag 1,5-Dihydro-pyrazolo[3,4-d]-pyrimidinon-derivate
DE10238723A1 (de) * 2002-08-23 2004-03-11 Bayer Ag Phenyl-substituierte Pyrazolyprimidine
DE10238724A1 (de) * 2002-08-23 2004-03-04 Bayer Ag Alkyl-substituierte Pyrazolpyrimidine
DE10238722A1 (de) * 2002-08-23 2004-03-11 Bayer Ag Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse
WO2004099211A1 (de) 2003-05-09 2004-11-18 Bayer Healthcare Ag 6-cyclylmethyl- und 6-alkylmethyl-substituierte pyrazolopyrimidine
JP2008524331A (ja) 2004-12-21 2008-07-10 武田薬品工業株式会社 ジペプチジルペプチダーゼ阻害剤
EP1919287A4 (en) 2005-08-23 2010-04-28 Intra Cellular Therapies Inc ORGANIC COMPOUNDS FOR TREATING A REDUCED DOPAMINE RECEPTOR SIGNALING ACTIVITY
US8012936B2 (en) 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
WO2008070095A1 (en) 2006-12-05 2008-06-12 Intra-Cellular Therapies, Inc. Novel uses
PT2152712E (pt) * 2007-05-11 2012-02-29 Pfizer Compostos amino-heterocíclicos
EP2227472A1 (en) 2007-11-30 2010-09-15 Elbion Gmbh Aryl and heteroaryl fused imidazo (1,5-a) pyrazines as inhibitors of phosphodiesterase 10
UA105362C2 (en) 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
CN102143965A (zh) 2008-09-08 2011-08-03 贝林格尔.英格海姆国际有限公司 吡唑并嘧啶酮及其在治疗中枢神经系统疾病中的用途
MX2011005934A (es) 2008-12-06 2011-12-16 Intra Cellular Therapies Inc Compuestos organicos.
TWI404721B (zh) 2009-01-26 2013-08-11 Pfizer 胺基－雜環化合物
EP2575817A4 (en) * 2010-05-31 2014-01-08 Intra Cellular Therapies Inc ORGANIC CONNECTIONS
EP3181566A1 (en) 2010-09-20 2017-06-21 Ironwood Pharmaceuticals, Inc. Imidazotriazinone compounds
US20130196986A1 (en) 2010-09-21 2013-08-01 Marc Labroli Triazolopyrazinones as p2x7 receptor antagonists
JO3089B1 (ar) 2010-11-19 2017-03-15 H Lundbeck As مشتقات ايميدازول كمثبطات لانزيمات pde10a
WO2012136552A1 (en) 2011-04-08 2012-10-11 H. Lundbeck A/S ANTIBODIES SPECIFIC TO PYROGLUTAMATED Αβ
EP2717877B1 (en) 2011-06-10 2017-11-08 Intra-Cellular Therapies, Inc. Organic compounds
MX381326B (es) 2011-10-10 2025-03-12 H Lundbeck As Derivados de 7h-imidazo[1-5-a]pirazin-8-ona como inhibidores de la fosfodiesterasa 9(pde9); y el uso de los mismos en el tratamiento de trastornos neurodegenerativos
EP2807163B1 (en) 2012-01-26 2017-03-22 H. Lundbeck A/S Pde9 inhibitors with imidazo triazinone backbone
US9499562B2 (en) 2012-06-18 2016-11-22 Dart Neuroscience (Cayman) Ltd. Substituted thiophene- and furan-fused azolopyrimidine-5-(6H)-one compounds
DK2970279T3 (da) 2013-03-15 2020-11-30 Intra Cellular Therapies Inc Organiske forbindelser
JP5783297B2 (ja) 2013-08-06 2015-09-24 株式会社デンソー 力学量センサ
TW201609713A (zh) * 2013-12-19 2016-03-16 Ｈ 朗德貝克公司 作爲ｐｄｅ１抑制劑之喹唑啉－ｔｈｆ－胺
JP5797815B1 (ja) 2014-06-27 2015-10-21 細田建設株式会社 後施工アンカー及びその施工方法
US20160083391A1 (en) 2014-09-18 2016-03-24 Sunovion Pharmaceuticals Inc. Tricyclic piperazine derivative
US20160083400A1 (en) 2014-09-18 2016-03-24 Sunovion Pharmaceuticals Inc. Tricyclic guanidine derivative
WO2016042775A1 (en) 2014-09-18 2016-03-24 Sunovion Pharmaceuticals Inc. Tricyclic derivative
TW201629064A (zh) 2014-10-10 2016-08-16 Ｈ 朗德貝克公司 作爲ｐｄｅ１抑制劑之三唑並吡酮
JP2018508555A (ja) 2015-03-16 2018-03-29 大日本住友製薬株式会社 二環性イミダゾロ誘導体
TW201643167A (zh) 2015-04-22 2016-12-16 Ｈ 朗德貝克公司 作爲ｐｄｅ１抑制劑之咪唑並三酮
JO3627B1 (ar) 2015-04-30 2020-08-27 H Lundbeck As إيميدازو بيرازينونات على هيئة مثبطات pde1
TWI609870B (zh) 2016-02-12 2018-01-01 美國禮來大藥廠 Pde1抑制劑
TWI729109B (zh) 2016-04-12 2021-06-01 丹麥商Ｈ 朗德貝克公司 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮
JP2018076285A (ja) 2016-09-14 2018-05-17 大日本住友製薬株式会社 二環性イミダゾロ誘導体を含む医薬
US10633382B2 (en) 2016-10-18 2020-04-28 H. Lundbeck A/S Imidazopyrazinones, pyrazolopyrimidinones and pyrazolopyridinones as PDE1 inhibitors
LT3532064T (lt) 2016-10-28 2020-09-25 H. Lundbeck A/S Kompleksiniai gydymai, apimantys imidazopirazonus, skirti psichiatrinių ir (arba) kognityvinių sutrikimų gydymui
RU2019108717A (ru) 2016-10-28 2020-11-30 Х. Лундбекк А/С Комбинированные средства для лечения, предусматривающего введение имидазопиразинонов

Also Published As

Publication number Publication date
ES2814289T3 (es) 2021-03-26
US10538525B2 (en) 2020-01-21
GEP20207057B (en) 2020-01-27
JP2019517996A (ja) 2019-06-27
NI201800092A (es) 2019-03-14
IL262257B (en) 2020-11-30
CY1123269T1 (el) 2021-12-31
TW201738242A (zh) 2017-11-01
RS60714B1 (sr) 2020-09-30
PT3442975T (pt) 2020-09-03
IL262257A (en) 2018-11-29
HRP20201331T1 (hr) 2020-11-27
DOP2018000201A (es) 2018-11-15
SMT202000446T1 (it) 2020-09-10
HUE050320T2 (hu) 2020-11-30
DK3442975T3 (da) 2020-08-24
MX2018012496A (es) 2019-02-21
LT3442975T (lt) 2020-09-25
CN109071549A (zh) 2018-12-21
ECSP18074641A (es) 2018-10-31
AU2017250431B2 (en) 2020-07-16
AU2017250431A1 (en) 2018-10-11
CN109071549B (zh) 2021-11-30
SV2018005753A (es) 2018-11-27
US20190194204A1 (en) 2019-06-27
CR20180470A (es) 2018-12-21
AR108109A1 (es) 2018-07-18
RU2018133391A (ru) 2020-05-12
EA035197B1 (ru) 2020-05-14
PL3442975T3 (pl) 2020-11-16
EP3442975B1 (en) 2020-07-29
EP3442975A1 (en) 2019-02-20
SI3442975T1 (sl) 2020-10-30
JP7093306B2 (ja) 2022-06-29
CO2018010323A2 (es) 2018-12-14
PE20181853A1 (es) 2018-12-03
MX374251B (es) 2025-03-05
CA3020053A1 (en) 2017-10-19
ME03820B (me) 2021-04-20
EA201891897A1 (ru) 2019-03-29
PH12018502168A1 (en) 2019-08-19
MA44656B1 (fr) 2020-10-28
SG11201808221QA (en) 2018-10-30
US11104680B2 (en) 2021-08-31
TWI729109B (zh) 2021-06-01
ZA201806407B (en) 2019-12-18
UA121925C2 (uk) 2020-08-10
US20200102316A1 (en) 2020-04-02
RU2018133391A3 (enExample) 2020-06-23
WO2017178350A1 (en) 2017-10-19
MY194722A (en) 2022-12-15
TN2018000321A1 (en) 2020-01-16
CL2018002881A1 (es) 2018-12-14
US20170291901A1 (en) 2017-10-12
BR112017026278A2 (pt) 2018-09-11
GEAP201914901A (en) 2019-09-25
MA44656A (fr) 2019-02-20

Similar Documents

Publication Publication Date Title
US10538525B2 (en) 1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-ones and 1,5-dihydro-4H-pyrazolo[4,3-c]pyridin-4-ones as PDE1 inhibitors
CN114423756B (zh) 取代的稠合杂芳双环化合物作为激酶抑制剂及其应用
JP6378785B2 (ja) Ｔａｎｋ結合キナーゼインヒビター化合物
AU2010311511B2 (en) Imidazo[1,2-b]pyridazine derivatives and their use as PDE10 inhibitors
ES2967489T3 (es) Imidazopirazinonas, pirazolopirimidinonas y pirazolopiridinonas como inhibidores de PDE1
KR20150065191A (ko) 헤테로방향족 화합물 및 도파민 d1 리간드로서 이의 용도
EP2828262A1 (en) Imidazotriazinone compounds
US20230136194A1 (en) Triazolopyridazine derivative, preparation method therefor, pharmaceutical composition thereof, and use thereof
US12162870B2 (en) Anticancer compounds
KR20190075068A (ko) 정신 및/또는 인지 장애의 치료를 위한 이미다조피라지논을 포함하는 병용 치료
JP2016508135A (ja) カゼインキナーゼ１ｄ／ｅ阻害剤としての新規なピラゾール置換のイミダゾピラジン
AU2012310168A1 (en) 6 - substituted 3 - (quinolin- 6 - ylthio) - [1,2,4] triazolo [4, 3 -a] pyradines as tyrosine kinase
KR20150023798A (ko) 항말라리아 제제로서의 피리미디논 유도체
US20240092784A1 (en) Condensed heterocyclic compound
HK40001748B (en) 1,5-dihydro-4h-pyrazolo[3,4-d]pyrimidin-4-ones and 1,5-dihydro-4h-pyrazolo[4,3-c]pyridin-4-ones as pde1 inhibitors
HK40001748A (en) 1,5-dihydro-4h-pyrazolo[3,4-d]pyrimidin-4-ones and 1,5-dihydro-4h-pyrazolo[4,3-c]pyridin-4-ones as pde1 inhibitors
WO2025255294A1 (en) Pkc-theta inhibitors, compositions, and methods of use
EA049140B1 (ru) Замещенные конденсированные гетероароматические бициклические соединения в качестве ингибиторов киназ и их применение

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20181011

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200317

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20210817

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20211020

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20210817

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I